A phase III randomized controlled study on the efficacy and improved bowel function of prolonged‐release (PR) oxycodone‐naloxone (up to 160/80 mg daily) vs oxycodone PR - Concepedia

Concepedia

Publication | Open Access

A phase III randomized controlled study on the efficacy and improved bowel function of prolonged‐release (PR) oxycodone‐naloxone (up to 160/80 mg daily) vs oxycodone PR

DOI Full Paper Access

32

Citations

8

References

2017

Year

Denis Dupoiron, Andrzej Stachowiak, O. Loewenstein, Adam Ellery, Walter K. Kremers, B. Bosse, Michael Hopp

European Journal of Pain

Abstract

Effective analgesia can be achieved using oxycodone/naloxone PR up to 160/80 mg daily without compromising bowel function. A similar outcome was reported in cancer and non-cancer patients.

References

	Year	Citations

Page 1